Citations

Clear

959 citation(s) found for "Service, F J".

On the Discorhabdins Leading to the Aleutianamine Ring System: A One‐Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology
Dickinson, Cody F. , Potluri, Abhay , Bland, Alison M. , Flipse, Samuel M., Hanna, George S., Wagner, Ryan T. , Ho, Thai H., Hoff, Gerald R., Stone, R. S., Tius, Marcus A. , Tantillo, Dean J., Hamann, Mark T., Dickinson, Cody F , Hanna, George S. , Robertson, Keith D. , Sprague, Daniel J. , Stone, Robert P., Tantillo, Dean J , Hamann, Mark T

Mayo Clinic

Angewandte Chemie | February 16, 2026 | Volume: 138 | Issue: 17 | Pages: No page available

10.1002/ange.7864883 Get It

ABSTRACT We disclose an efficient transformation of the relatively common pyrroloiminoquinone discorhabdin alkaloids from Alaskan Latrunculia spp. to the complex ring system of aleutianamine by an acid catalyzed process that mimics the proposed endogenous genesis from 3‐dihydrodienyl discorhabdin precursors. The azepine ring system is formed by a concerted 1,2‐alkyl shift of a proposed thiocarbenium‐iminium dication and this mechanism is supported by extensive density functional theory (DFT) analysis. Additional in vitro biological data further supports the aleutianamines as novel and highly potent inhibitors of multidrug resistant cancer lines exemplified further with cytotoxicity toward chemotherapy resistant chromophobe renal cell carcinoma (IC 50 = 130 nM). This report provides a key transformation that allows the incorporation of either synthetic or biosynthetic starting materials leading to the generation of the aleutianamine complex ring system in just a single step from the discorhabdin ring system.
On the Discorhabdins Leading to the Aleutianamine Ring System: A One‐Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology
Potluri, Abhay , Bland, Alison M. , Flipse, Samuel M., Hanna, George S., Wagner, Ryan T. , Ho, Thai H., Sprague, Daniel J. , Hoff, Gerald R., Stone, R. S., Tius, Marcus A. , Tantillo, Dean J., Hamann, Mark T., Dickinson, Cody F , Tantillo, Dean J , Hamann, Mark T , Dickinson, Cody F. , Hanna, George S. , Robertson, Keith D. , Stone, Robert P.

Mayo Clinic

Angewandte Chemie International Edition | February 16, 2026 | Volume: 65 | Issue: 17 | Pages: No page available

10.1002/anie.7864883 | PMID 41693117 Get It

ABSTRACT We disclose an efficient transformation of the relatively common pyrroloiminoquinone discorhabdin alkaloids from Alaskan Latrunculia spp. to the complex ring system of aleutianamine by an acid catalyzed process that mimics the proposed endogenous genesis from 3‐dihydrodienyl discorhabdin precursors. The azepine ring system is formed by a concerted 1,2‐alkyl shift of a proposed thiocarbenium‐iminium dication and this mechanism is supported by extensive density functional theory (DFT) analysis. Additional in vitro biological data further supports the aleutianamines as novel and highly potent inhibitors of multidrug resistant cancer lines exemplified further with cytotoxicity toward chemotherapy resistant chromophobe renal cell carcinoma (IC 50 = 130 nM). This report provides a key transformation that allows the incorporation of either synthetic or biosynthetic starting materials leading to the generation of the aleutianamine complex ring system in just a single step from the discorhabdin ring system.
Pre-Radioiodine Thyrotropin Thresholds During Withdrawal Preparation in Differentiated Thyroid Cancer after Total Thyroidectomy: A Systematic Review and Meta-Analysis
Rojas, Tatiana , Solís-Pazmiño, Paola , Figueroa, Luis , Ledesma, Tannya, Solis-Pazmino, Paola , Pazmino-Chavez, Camila, Naranjo, Eddy P. Lincango, Tite-Haro, María Belén , Alvarado-Mafla, Benjamin , Barrera-Flores, Francisco J., Nasseri, Yosef, Cohen, Jason, Toro-Tobon, David, Ponce, Oscar J., Figueroa, Luis A , Ledesma, Tannya M , Pilatuna, Eduardo A , Pazmino-Chavez, Camila N , Lincango Naranjo, Eddy P , Naranjo, Eddy P Lincango, Nasseri, Yosef , Toro-Tobón, David , Ponte, Oscar Ponce, Brito, Juan P.

Mayo Clinic

Thyroid® | February 12, 2026 | Volume: 36 | Issue: 3 | Pages: 229-241

10.1177/10507256261423206 | PMID 41674098 Get It

Background: Preparation for radioiodine (RAI) therapy in differentiated thyroid cancer (DTC) often requires thyroid hormone withdrawal (THW) to achieve thyrotropin (TSH) stimulation. Current guidelines recommend TSH ≥30 mIU/L, a target that prolongs hypothyroidism and worsens quality of life, yet rests on limited evidence. Objective: To evaluate the association between pre-RAI TSH levels and oncologic outcomes in adults with DTC prepared by THW. Methods: We conducted a systematic review and meta-analysis of studies comparing outcomes across pre-RAI TSH thresholds (<30 vs. ≥30, <60 vs. ≥60, and <90 vs. ≥90 mIU/L) in adults with DTC prepared by THW. Primary outcomes included disease-specific mortality, recurrence, and response to therapy. Searches in MEDLINE, Embase, Cochrane, and Scopus (inception to March 2025) identified eligible studies. Risk of bias was assessed using the CLARITY tool and certainty of evidence using GRADE. Pooled relative risks (RRs) were calculated using random-effects models. This systematic review was registered in PROSPERO (CRD42020158354). Results: This meta-analysis included eight retrospective cohort studies comprising a total of 4651 DTC patients, predominantly women (68.5%) with a mean age of 46 years. All patients underwent THW before RAI. Across all TSH thresholds examined (<30, <60, and <90 mIU/L), higher pre-RAI TSH levels were not associated with better treatment response, lower recurrence, or reduced mortality. Specifically, patients with higher pre-RAI TSH levels (≥30 mIU/L) did not have better oncologic outcomes compared with those with lower levels (<30 mIU/L). At 2- and 3-year follow-up, no significant differences were observed in excellent (pooled RR = 0.87; confidence interval [CI] 0.68–1.11) or indeterminate (RR = 1.28; CI 0.72–2.27) response rates. Similarly, recurrence rates did not differ (RR = 1.45; CI 0.83–2.55), and no study demonstrated a difference in disease-specific mortality across follow-up periods extending up to 10 years. The certainty of evidence for all outcomes was rated very low due to risk of bias, heterogeneity, and imprecision. Conclusions: The current evidence base is insufficient to support or refute the routine use of a specific TSH threshold before RAI administration. These findings question the recommendation to achieve TSH ≥30 mIU/L before RAI and highlight the need for trials to define the minimal effective level of TSH stimulation.
Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome
Rubino, Selene , Cannon, Grant W. , Sauer, Brian C. , Rojas, Jorge, Stoddard, Gregory J. , Kunkel, Gary, England, Bryant R, Baker, Joshua F, Braaten, Tawnie , England, Bryant R. , Walsh, Jessica A , England, Bryant R , Sauer, Brian C , Cannon, Grant W , Baker, Joshua F.

Mayo Clinic

Arthritis Care & Research | February 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acr.80015 | PMID 41664543 Get It

Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients. Methods We performed a national retrospective cohort study of US veterans treated with an ICI between June 2011 and February 2022. Cases were identified by elevated creatinine kinase (CK) following ICI therapy and/or “myositis” in notes. Chart review determined if candidates had ICI‐associated myositis and were subsequently classified as isolated ICI myositis or ICI triad syndrome. Results Of 29,296 veterans treated with ICIs, 68 (0.2%) ICI‐induced myositis cases were identified, including 23 patients with ICI triad syndrome and 45 patients with isolated ICI myositis. Median survival duration for ICI triad syndrome was 2.5 (95% confidence interval [CI] 1.7–18.5) months in comparison to 20.4 (95% CI 6.2–60) months for isolated ICI myositis and 12.6 (95% CI 12.3–12.8) months median survival for patients treated with ICI without myositis. Patients with ICI triad syndrome had 60.0% mortality during the six months following initiation of ICI treatment, in comparison to 30.2% mortality in isolated ICI myositis and 31.5% mortality in patients without myositis. Six months after the first ICI treatment, subsequent mortality trends were similar in the three groups. Conclusion ICI triad syndrome is associated with higher overall mortality and shortened median survival times during the first six months after initial ICI therapy, whereas isolated ICI myositis is associated with similar mortality outcomes compared to patients treated with ICI who did not develop myositis. image
Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve
Thériault, Sébastien , Holdcraft, Jacob A., Sharipova, Dinara , Dębiec, Radosław , Peloso, Gina M., Al‐Kassou, Baravan , Swan, Elena Ashikhmina , Ballotta, Andrea, Björck, Hanna M. , Braund, Peter S. , Corriveau, François, Dagenais, François, Francke, Michael, Gorbatov, Svetlana, Guo, Dongchuan, Habchi, Karam M, Scouarnec, Solena Le , Lichtner, Peter , Nguyen, Thy B., Norris, R., Pibarot, P, Simonet, Floriane, Tm, Sundt, Tessler, Idit , Willer, Cristen J., Wittmann, Susanne, Yang, Bo, Berezovets, Igor, Doppler, S. , Dreßen, Martina, Knoll, Katharina, Puehler, T., Schunkert, H, Bissell, Malenka M. , Bolger, Aidan, Brion, M, Citro, Rodolfo, Deeb, G. Michael, Corte, Alessandro Della, Dina, C., Eriksson, Per, Evangelista, Arturo , Franco-Cereceda, Anders, Gilon, Dan, Hetherington, Simon, Huggins, G S, Krane, Markus , Tourneau, Thierry Le, Limongelli, Giuseppe, Mathieu, P., Messika-Zeitoun, David, Michelena, Hector I., Milewicz, Dianna, Murdock, David R. , Nickenig, G., Nistri, Stefano, Nöthen, M, Samani, Nilesh J. , Schott, J., Webb, Tom R., Abdelilah-Seyfried, Salim, Schumacher, Johannes, Trenkwalder, Teresa , Body, Simon C. , Dina, Christian , Brión, Marı́a , Peloso, Gina M. , Webb, Tom R. , Faucherre, Adèle , Debiec, Radoslaw M , Peloso, Gina M , Al-Kassou, Baravan , Aranki, Sary , Ashikhmina Swan, Elena , Björck, Hanna M , Boureau, Anne Sophie , Braund, Peter S , Folkersen, Lasse , Guo, Dongchuan , Heydarpour, Mahyar , Isselbacher, Eric M , Jopling, Chris , Laporte, Fabien , Le Scouarnec, Solena , Li, Zhonglin , Lichtner, Peter , Maj, Carlo , Manikpurage, Hasanga D , Nguyen, Thy B , Norris, Russell A , Pibarot, Phillippe , Sarubbi, Berardo , Simonet, Floriane , Sundt, Thoralf , Surakka, Ida , Tessler, Idit , Yang, Bo , Doppler, Stefanie A , Dreßen, Martina , Knoll, Katharina , Puehler, Thomas , Schunkert, Heribert , Bissell, Malenka M , Bossé, Yohan , Bossone, Eduardo , Brion, María , Citro, Rodolfo , de Vincentiis, Carlo , Deeb, G Michael , Della Corte, Alessandro , Dina, Christian , Durst, Ronen , Ensminger, Stephan , Eriksson, Per , Evangelista, Arturo , Franco-Cereceda, Anders , Gilon, Dan , Giusti, Betti , Hetherington, Simon L , Huggins, Gordon S , Le Tourneau, Thierry , Limongelli, Giuseppe , Mathieu, Patrick , Messika-Zeitoun, David , Michelena, Hector I , Milewicz, Dianna M , Muehlschlegel, Jochen D , Murdock, David R , Nickenig, Georg , Nistri, Stefano , Nöthen, Markus M , Prakash, Siddharth K , Samani, Nilesh J , Jacques Schott, Jean , Webb, Tom R , Zaffran, Stéphane , Eagle, Kim , Body, Simon C , Holdcraft, Jacob A., Bellino, Michele , Dagenais, François, Forte, Amalia , Frigiola, Alessandro , Guo, Dongchuan , Isselbacher, Eric M. , Nelson, Christopher P. , Ong, Chin Siang , Roychowdhury, Tanmoy , Surakka, Ida , Willer, Cristen J , Aviérinos, Jean-François , Bolger, Aidan P. , Bossé, Yohan , Bossone, Eduardo , Citro, Rodolfo , Deeb, G. Michael , Corte, Alessandro Della , Gilon, Dan, Huggins, Gordon S. , Tourneau, Thierry Le , Mathieu, Patrick , Messika–Zeitoun, David , Nistri, Stefano , Nöthen, Markus M. , Pluchinotta, Francesca Romana , Prakash, Siddharth K. , Schott, Jean‐Jacques , Zaffran, Stéphane , Abdelilah‐Seyfried, Salim , Eagle, Kim A. , Schumacher, Johannes

Mayo Clinic

Circulation | February 6, 2026 | Volume: 153 | Issue: 14 | Pages: 1060-1076

10.1161/circulationaha.125.074752 | PMID 41645906 Get It

BACKGROUND: Bicuspid aortic valve (BAV) is a frequent congenital heart defect with a high heritability. Despite this, only a limited number of genes have been associated with the disease, and the molecular mechanisms remain unexplained in most cases. This study aimed to further understand the genetic architecture of BAV. METHODS: A genome-wide association study meta-analysis including 9631 cases among 65 677 participants was performed. Genes were prioritized using transcriptomic analyses based on RNA sequencing in relevant tissues, including human fetal and adult aortic valves. The impact of the knockdown or knockout of 4 candidate genes on cardiac development was verified in zebrafish. A polygenic risk score was developed, its association with BAV was evaluated in an independent cohort, and its association with a wide range of phenotypes (n=976) was evaluated in UK Biobank (n=355 618 individuals). RESULTS: Thirty-six genomic loci were identified, including 32 that were not described previously. Among the prioritized genes, KANK2 and ERBB4 were identified as potentially causal through transcriptomic analyses, colocalization, and Mendelian randomization based on gene expression in human aortic valves (n=484), whereas PRDM6 and STRN were prioritized using similar analyses from aortic (n=326) and left ventricular tissues (n=326), respectively. Targeting 4 candidate genes ( WNT4 , LEF1 , STRN , and KANK2 ) in zebrafish led to disruption in cardiac development. A polygenic risk score was associated with an odds ratio of 2.07 (95% CI, 1.90–2.25; P =5.43×10 -62 ) per SD for BAV and significantly associated with thoracic aortic aneurysm and atrial fibrillation in UK Biobank. CONCLUSIONS: This study supports a significant polygenic contribution to BAV, where the combination of multiple common variants in genes involved in heart morphogenesis disrupts aortic valve development.
Shared Pathogenic Pathways Between REM Sleep Behavior Disorder and Neurodegenerative and Psychiatric Disorders
Zhang, Zhao, Somerville, Emma N. , Fang, Zih‐Hua , Liu, Lang, Asayesh, Farnaz , Ahmad, Jamil, Amiri, Saeid , Teferra, Meron, Dodet, P., Arnulf, Isabelle, Hu, Michele T.M., Desautels, A., Dauvilliers, Yves, Aktan-Süzgün, Merve , Stefani, A., Högl, Birgit, Gaig, Carles, Mayà, G., Iranzo, Alex, Serradell, Mònica , Valente, Mariarosaria, Dusek, P., Sommerauer, Michael , Röttgen, Sinah, Figorilli, M., Puligheddu, Monica, Mollenhauer, Brit, Trenkwalder, Claudia, Sixel-Doring, Friederike, Plazzi, G., Antelmi, E., Terzaghi, Michele, Fiamingo, Giuseppe , Ferini-Strambi, Luigi, Kulcsarova, Kristina, Bušková, J., Abril, Beatriz, Orso, B., Arnaldi, D., Boeve, Bradley F., Ju, Yo‐El S. , Ross, Owen A., Wu, Shih-Ying, Lee, Jonghun , Prilutsky, Daria, Blauwendraat, Cornelis, Leonard, Hampton, Postuma, Ronald B., Rouleau, Guy A., Gan-Or, Ziv, Arnulf, Isabelle , Hu, Michele T M , Desautels, Alex , Dauvilliers, Yves , Ibrahim, Abubaker , Stefani, Ambra , Högl, Birgit , Montini, Angelica , Maya, Gerard , Serradell, Monica , Gigli, Gian Luigi , Valente, Mariarosaria , Janes, Francesco , Sonka, Karel , Kemlink, David , Dušek, Petr , Figorilli, Michela , Puligheddu, Monica , Mollenhauer, Brit , Trenkwalder, Claudia , Sixel-Doring, Friederike , Plazzi, Giuseppe , Biscarini, Francesco , Antelmi, Elena , Cochen De Cock, Valérie , Terzaghi, Michele , Fiamingo, Giuseppe , Heidbreder, Anna , Ferini-Strambi, Luigi , Ostrozovicova, Miriam , Skorvanek, Matej , Kulcsarova, Kristina , Buskova, Jitka , Orso, Beatrice , Mattioli, Pietro , Arnaldi, Dario , Boeve, Brad , Ross, Owen A , Blauwendraat, Cornelis , Postuma, Ronald B , Rouleau, Guy Armand , Gan-Or, Ziv , Zhang, Zhao , Liu, Lang , Ahmad, Jamil, Teferra, Meron , Dodet, Pauline , Arnulf, Isabelle , Désautels, Alex , Dauvilliers, Yves , Ibrahim, Abubaker , Stefani, Ambra , Högl, Birgit , Gaig, Carles , Mayà, Gerard , Iranzo, Álex , Serradell, Mónica , Janes, Francesco , Bernardini, Andrea , Šonka, Karel , Dušek, Petr , Röttgen, Sinah , Figorilli, Michela , Puligheddu, Monica , Mollenhauer, Brit , Trenkwalder, Claudia , Sixel‐Döring, Friederike , Biscarini, Francesco , Antelmi, Elena, Heidbreder, Anna , Kulcsárová, Kristína , Mattioli, Pietro , Arnaldi, Dario , Boeve, Bradley F. , Blauwendraat, Cornelis , Postuma, Ronald B. , Gan‐Or, Ziv

Mayo Clinic

No container title available | February 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.05.26345599 | PMID 41674635 Get It

Abstract Isolated/idiopathic rapid-eye-movement (REM)-Sleep Behavior Disorder (iRBD) is characterized by dream enactment behaviors associated with loss of REM atonia. iRBD is in most cases a prodromal synucleinopathy, and emerging evidence suggests associations between RBD and other neurological and psychiatric conditions. In this study, we performed pathway-based polygenic risk score (PRS) and rare variant burden analyses to examine these potential associations. Pathway-specific PRS were constructed from genome-wide association study summary statistics of five neurodegenerative and seven psychiatric traits across 10 biologically relevant pathway categories, including a total of 279 pathways, in 1,573 iRBD cases and 16,022 controls from the International RBD Study Group and UK Biobank. Rare variant burden tests were performed in 1,264 iRBD cases and 2,581 controls. We identified multiple potential pathways indicating shared polygenic risk between RBD and both neurodegenerative and psychiatric disorders. Lewy body diseases and post-traumatic stress disorder had the most shared polygenic risk pathways in neurological and psychiatric disorders, respectively. Two pathways, the serotonin transport pathway and the chaperone-mediated autophagy pathway, showed the strongest association with iRBD, and gene-based rare variants analyses revealed five genes associated with iRBD: GBA1 , PLEKHM1 , LRP2 , P2RX1 , and HAP1. Subsequent analysis of these genes in Parkinson’s disease and dementia with Lewy bodies replicated several associations. Together, these findings provide novel insights into the shared genetic architecture underlying iRBD, neurodegenerative disorders, and psychiatric traits, with implications for early identification and mechanistic understanding.
Fertility Preservation in Female Cancer Patients: Comprehensive Clinical, Surgical, and Radiologic Guide for Radiologists
Aineseder, Martina , Hassanzadeh, Sara, Lorea, Mariano , Venkatesan, Aradhana M. , Langstraat, Carrie L., Pesce, Romina , Lakhman, Yulia, Chacon, Carolina R. B., Andrieu, Pamela I. Causa, Langstraat, Carrie , Lakhman, Yulia , Langstraat, Carrie L , Ainsworth, Alessandra J. , Odetto, Diego , Lakhman, Yulia , Causa Andrieu, Pamela , Venkatesan, Aradhana M , Odetto, Diego , Andrieu, Pamela Causa

Mayo Clinic

RadioGraphics | February 5, 2026 | Volume: 46 | Issue: 3 | Pages: No page available

10.1148/rg.250026 | PMID 41642727 Get It

A comprehensive approach that combines imaging, histopathologic analysis, and patient counseling can be used to develop personalized fertility-sparing and fertility-preserving protocols that are safe and effective and respect patient autonomy in making decisions related to their future fertility.
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
Shadman, Mazyar, Chanan‐Khan, Asher , Campbell, David , Xue, Mei, Massoudi, Marjan , Williams, Rhys, Yang, Keri, Tam, Constantine S., Tam, Constantine S. , Shadman, Mazyar , Shadman, Mazyar , Xue, Mei , Tam, Constantine S , Williams, Rhys

Mayo Clinic

Future Oncology | January 31, 2026 | Volume: 22 | Issue: 3 | Pages: 339-348

10.1080/14796694.2026.2615736 | PMID 41618895 Get It

Chimerism and a framework for clinical practice: A report from the Cellular Therapies Section Coordinating Committee ( CTSCC ) of Association for Advancement of Blood and Biotherapies (
Guleria, Indira , Connelly‐Smith, Laura , Bapat, Asawari , Klein, Monica, Jacob, Eapen K., Mahanta, Simran, Cui, Wanxing, Reich‐Slotky, Ronit , Spitzer, Thomas R. , Connelly-Smith, Laura , Bapat, Asawari, Alkhateeb, Hassan B. , Anandappa, Annabelle J. , Cui, Wanxing , Celluzzi, Christina M.

Mayo Clinic

Transfusion | January 28, 2026 | Volume: 66 | Issue: 8 | Pages: 1624-1644

10.1111/trf.70095 | PMID 41603138 Get It

Transulnarversus transradial artery access in patients undergoing cardiac procedures: a systematic review and meta-analysis
Al-Shamari, Mohamed Falah Abdullah, Zreigh, Sofian , Waqas, Daniya, Htet, Yamin , Iqbal, Iqra, Ashraf, Efrah, Javaid, Sana, Farooq, Imshal, Feyisa, Milikyas Abera, Rehman, Mohammad Ebad Ur , Alsubari, Asma’a Munasar Ali, Nashwan, Abdulqadir J. , Mohammad, Ameen Mosa , Ahmad, Adeel, Rehman, Wajeeh Ur , Ahmed, Raheel , Munasar Ali Alsubari, Asma'a , Mosa, Ahmed A. , Htet, Yamin, Iqbal, Iqra, Cheema, Huzaifa Ahmad

Mayo Clinic

Annals of Medicine & Surgery | January 20, 2026 | Volume: 88 | Issue: 2 | Pages: 1806-1814

10.1097/ms9.0000000000004696 | PMID 41675798 Get It

Background: Transradial artery access (TRA) is the favored approach for percutaneous coronary intervention (PCI) and coronary angiography (CAG). However, transulnar artery access (TUA) has emerged as an alternative, particularly when TRA is not feasible. This systematic review and meta-analysis aims to compare the efficacy and safety of TUA versus TRA in patients undergoing PCI and CAG. Methods: From inception to August 2025, a systematic search of electronic databases was conducted. Data were synthesized using a random-effects model, and heterogeneity was assessed using the I 2 statistic. Results: Nine RCTs involving 6089 patients were included. Meta-analysis revealed no significant difference in procedural success between TUA and TRA (RR: 0.93, 95% CI: 0.82–1.06, P = 0.28, I 2 = 99%). Similarly, puncture success rates were comparable (RR: 0.95, 95% CI: 0.91–1.00, P = 0.06, I 2 = 83%). Secondary outcomes showed no significant differences in puncture attempts or hematoma incidence, but TRA was associated with a shorter procedure time (MD: 0.89, 95% CI: 0.27–1.50, P = 0.005). Conclusion: TUA provides a viable alternative to TRA, with similar success rates and complication profiles. However, TRA remains superior in terms of procedure time. Further large-scale RCTs are warranted to confirm these findings and refine clinical guidelines.